Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Agenus Inc. (AGEN) for alleged misstatements and omissions related to the effectiveness of its botensilimab and balstilimab combination therapy. Investors who suffered losses exceeding $50,000 are encouraged to contact the firm to discuss their legal rights.